FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2993022840> ?p ?o ?g. }

• W2993022840 endingPage "82" @default.
• W2993022840 startingPage "74" @default.
• W2993022840 abstract "Purpose: To characterize the T cell receptor (TCR) repertoire, serum cytokine levels, peripheral blood T lymphocyte populations, safety, and clinical efficacy of hyperthermia (HT) combined with autologous adoptive cell therapy (ACT) and either salvage chemotherapy (CT) or anti-PD-1 antibody in patients with previously treated advanced solid tumors.Materials and methods: Thirty-three (33) patients with ovarian, pancreatic, gastric, colorectal, cervical, or endometrial cancer were recruited into the following therapeutic groups: HT + ACT (n = 10), HT + ACT + anti-PD-1 inhibitor (pembrolizumab) (n = 11) and HT + ACT + CT (n = 12). Peripheral blood was collected to analyze TCR repertoire, measurements of cytokines levels and lymphocyte sub-populations before and after treatment.Results: The objective response rate (ORR) was 30% (10/33), including three complete responses (CR) (9.1%) and seven partial responses (PR) (21.2%) and a disease control rate (DCR = CR + PR + SD) of 66.7% (22 of 33). The most common adverse reactions, blistering, subcutaneous fat induration, local heat-related pain, vomiting and sinus tachycardia, were observed in association with HT. IL-2, IL-4, TNF-α, and IFN-γ levels in peripheral blood were significantly increased among the clinical responders (p < 0.05) while IL-6 and IL-10 were elevated among those with progressive disease (p < 0.05). Peripheral blood CD8+/CD28+ T cells increased (p = 0.002), while the CD4+/CD25+/CD127+Treg cells decreased after therapy (p = 0.012). TCR diversity was substantially increased among the clinical responders.Conclusions: Combining HT with ACT plus either CT or anti-PD-1 antibody was safe, generated clinical responses in previously treated advanced cancers, and promoted TCR repertoire diversity and favorable changes in serum IL-2, IL-4, TNF-α, and IFN-γ levels in clinical responders." @default.
• W2993022840 created "2019-12-13" @default.
• W2993022840 creator A5002432637 @default.
• W2993022840 creator A5006277770 @default.
• W2993022840 creator A5012804507 @default.
• W2993022840 creator A5027941146 @default.
• W2993022840 creator A5032451475 @default.
• W2993022840 creator A5038382011 @default.
• W2993022840 creator A5044590253 @default.
• W2993022840 creator A5045134210 @default.
• W2993022840 creator A5050464467 @default.
• W2993022840 creator A5053513964 @default.
• W2993022840 creator A5054014646 @default.
• W2993022840 creator A5071949435 @default.
• W2993022840 creator A5074731037 @default.
• W2993022840 creator A5075442335 @default.
• W2993022840 creator A5083239520 @default.
• W2993022840 creator A5087099599 @default.
• W2993022840 date "2019-11-29" @default.
• W2993022840 modified "2023-09-30" @default.
• W2993022840 title "Immune correlates of clinical benefit in a phase I study of hyperthermia with adoptive T cell immunotherapy in patients with solid tumors" @default.
• W2993022840 cites W1513881469 @default.
• W2993022840 cites W1572554526 @default.
• W2993022840 cites W1631661663 @default.
• W2993022840 cites W1845151816 @default.
• W2993022840 cites W1969539968 @default.
• W2993022840 cites W1973639800 @default.
• W2993022840 cites W1976693775 @default.
• W2993022840 cites W1982322400 @default.
• W2993022840 cites W2002449811 @default.
• W2993022840 cites W2003485639 @default.
• W2993022840 cites W2005014624 @default.
• W2993022840 cites W2028253685 @default.
• W2993022840 cites W2042669918 @default.
• W2993022840 cites W2049028002 @default.
• W2993022840 cites W2052404907 @default.
• W2993022840 cites W2059137774 @default.
• W2993022840 cites W2076232417 @default.
• W2993022840 cites W2076668534 @default.
• W2993022840 cites W2099253077 @default.
• W2993022840 cites W2102862705 @default.
• W2993022840 cites W2109117547 @default.
• W2993022840 cites W2112056290 @default.
• W2993022840 cites W2112391258 @default.
• W2993022840 cites W2113041457 @default.
• W2993022840 cites W2140344120 @default.
• W2993022840 cites W2150333647 @default.
• W2993022840 cites W2191128059 @default.
• W2993022840 cites W2259404274 @default.
• W2993022840 cites W2463030500 @default.
• W2993022840 cites W2560419584 @default.
• W2993022840 cites W2589361933 @default.
• W2993022840 cites W2625028514 @default.
• W2993022840 cites W2735105612 @default.
• W2993022840 cites W2801166095 @default.
• W2993022840 cites W2806426611 @default.
• W2993022840 cites W2808727488 @default.
• W2993022840 cites W2888750407 @default.
• W2993022840 cites W2900015447 @default.
• W2993022840 cites W2902941439 @default.
• W2993022840 cites W2937667996 @default.
• W2993022840 cites W1971068427 @default.
• W2993022840 doi "https://doi.org/10.1080/02656736.2019.1647350" @default.
• W2993022840 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31795830" @default.
• W2993022840 hasPublicationYear "2019" @default.
• W2993022840 type Work @default.
• W2993022840 sameAs 2993022840 @default.
• W2993022840 citedByCount "19" @default.
• W2993022840 countsByYear W29930228402020 @default.
• W2993022840 countsByYear W29930228402021 @default.
• W2993022840 countsByYear W29930228402022 @default.
• W2993022840 countsByYear W29930228402023 @default.
• W2993022840 crossrefType "journal-article" @default.
• W2993022840 hasAuthorship W2993022840A5002432637 @default.
• W2993022840 hasAuthorship W2993022840A5006277770 @default.
• W2993022840 hasAuthorship W2993022840A5012804507 @default.
• W2993022840 hasAuthorship W2993022840A5027941146 @default.
• W2993022840 hasAuthorship W2993022840A5032451475 @default.
• W2993022840 hasAuthorship W2993022840A5038382011 @default.
• W2993022840 hasAuthorship W2993022840A5044590253 @default.
• W2993022840 hasAuthorship W2993022840A5045134210 @default.
• W2993022840 hasAuthorship W2993022840A5050464467 @default.
• W2993022840 hasAuthorship W2993022840A5053513964 @default.
• W2993022840 hasAuthorship W2993022840A5054014646 @default.
• W2993022840 hasAuthorship W2993022840A5071949435 @default.
• W2993022840 hasAuthorship W2993022840A5074731037 @default.
• W2993022840 hasAuthorship W2993022840A5075442335 @default.
• W2993022840 hasAuthorship W2993022840A5083239520 @default.
• W2993022840 hasAuthorship W2993022840A5087099599 @default.
• W2993022840 hasBestOaLocation W29930228401 @default.
• W2993022840 hasConcept C121608353 @default.
• W2993022840 hasConcept C126322002 @default.
• W2993022840 hasConcept C167672396 @default.
• W2993022840 hasConcept C203014093 @default.
• W2993022840 hasConcept C2776090121 @default.
• W2993022840 hasConcept C2777701055 @default.
• W2993022840 hasConcept C71924100 @default.
• W2993022840 hasConcept C8891405 @default.

• next